Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug 6;10:44.
doi: 10.1186/1472-6882-10-44.

Maca (L. Meyenii) for Improving Sexual Function: A Systematic Review

Affiliations
Free PMC article
Review

Maca (L. Meyenii) for Improving Sexual Function: A Systematic Review

Byung-Cheul Shin et al. BMC Complement Altern Med. .
Free PMC article

Abstract

Background: Maca (Lepidium meyenii) is an Andean plant of the brassica (mustard) family. Preparations from maca root have been reported to improve sexual function. The aim of this review was to assess the clinical evidence for or against the effectiveness of the maca plant as a treatment for sexual dysfunction.

Methods: We searched 17 databases from their inception to April 2010 and included all randomised clinical trials (RCTs) of any type of maca compared to a placebo for the treatment of healthy people or human patients with sexual dysfunction. The risk of bias for each study was assessed using Cochrane criteria, and statistical pooling of data was performed where possible. The selection of studies, data extraction, and validations were performed independently by two authors. Discrepancies were resolved through discussion by the two authors.

Results: Four RCTs met all the inclusion criteria. Two RCTs suggested a significant positive effect of maca on sexual dysfunction or sexual desire in healthy menopausal women or healthy adult men, respectively, while the other RCT failed to show any effects in healthy cyclists. The further RCT assessed the effects of maca in patients with erectile dysfunction using the International Index of Erectile Dysfunction-5 and showed significant effects.

Conclusion: The results of our systematic review provide limited evidence for the effectiveness of maca in improving sexual function. However, the total number of trials, the total sample size, and the average methodological quality of the primary studies were too limited to draw firm conclusions. More rigorous studies are warranted.

Figures

Figure 1
Figure 1
Flow chart for the selection of included trials. RCT: randomised clinical trial; UOS: uncontrolled observational study.

Similar articles

See all similar articles

Cited by 15 articles

See all "Cited by" articles

References

    1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–544. doi: 10.1001/jama.281.6.537. - DOI - PubMed
    1. Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, Rellini AH, Segraves T. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2):1598–1607. doi: 10.1111/j.1743-6109.2010.01778.x. - DOI - PubMed
    1. Phillips NA. Female sexual dysfunction: evaluation and treatment. Am Fam Physician. 2000;62(1):127–136. 141-122. - PubMed
    1. Morales AM, Mirone V, Dean J, Costa P. Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging. 2009;4:463–472. - PMC - PubMed
    1. Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M. et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650–661. - PubMed
Feedback